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ABSTRACT 
Proximal esophageal cancer (PEC) is a highly mortal cancer 
with a five-year survival rate of 30%. Because second 
primary tumors could decrease survival in PEC patients, this 
research is aiming at finding out about tumors associated 
with PEC and their infuence on survival. With the use of a 
database with PEC patients, diagnosed between 1989 and 
2014, it was found that head and neck cancers (H&N) are 
the most prevalent previous tumor in PEC patients. Previous 
tumors have a negative effect on surivval. Prospective 
studies are needed to investigate on the effectiveness of 
prevention and surveillance methods for H&N patients. 
Keywords 
proximal esophageal cancer, previous tumors, survival 
 
INTRODUCTION 
The proximal esophagus is located between the inferior 
border of the cricoid cartilage and the carina, up to 24 cm 
from the incisor teeth. A special part of the proximal 
esophagus is the cervical esophagus, which extents 18 cm 
from the incisor teeth. Tumors of the cervical esophagus, 
which is the most complex part of the proximal esophagus, 
is an uncommon disease accounting for around 2 to 10% of 
all esophageal cancers (EC) (1). Its complexity originates 
from the fact that  is located between the thoracic inlet and 
the inferior border of the cricoid cartilage with proximity to 
adjacent structures like the thyroid gland, thyroid cartilage 
and cricoid. Histology of this cancer is squamous cell 
carcinoma (SCC) in 95% of the cases (2). 
Esophageal squamous cell carcinoma (ESCC) in general and 
cancer of the proximal esophagus (PEC) in specific have 
shown to be associated with cancer of the lung, head and 
neck (H&N), which was shown is prior studies The 
incidence of ESCC in H&N cancer is 12.4% according to a 
study by Laohawiiyakamol et al. (13).. ESCC is associated 
with colorectal cancer and  with cancers of the oral cavity, 
the pharynx, larynx, the lung, kidney, thyroid and bladder 
(14, 15). Furthermore, studies have shown that second 
primary tumors in patients with H&N tumors can influence 
survival of cancer patients, as survival is lower in patients 
who have a H&N subsequent  cancer compared to no cancer 
at all (16). Lee et al. has shown that survival is decreased in 
a patient group of ESCC when patients present with a 
synchronous malignancy (17). The development of second 
primary tumors (SPT) is enhanced by shared risk factors of 
PEC and tumors of the upper aerodigestive tract (UADT), 
like tobacco smoking and alcohol abuse (19). The effect of 
these risk factors is enhanced when the esophagus suffers 
mechanical damage, which can be case in achalasia or a 
consequence of administration of sodium hydroxide (20, 
21). 
The presence of other tumors in a locally related area is often 
explained by the term “field cancerization”. The core 
concept of this theory is that there is an area adjacent to the 
tumor which shows some pre-malignant genetic mutations 
and therefore is of high risk of becoming entirely malignant, 
which can be enhanced by the previously mentioned risk 
factors alcohol and tobacco consumption (7).  
Irradiation by e.g. radiotherapy can also be an important 
inducer of second primary cancer, as the radiation causes 
DNA damage and increase the probability of these cells to 
become malignant. There is evidence that therapeutic 
radiation of H&N cancer can cause ESCC via damage of the 
DNA and therefore increase the potential of cells turning into 
malignancies (22).  
Zhang et al. and Hashibe et al. have shown has shown that 
irradiation can cause the formation of SPT, with a 
development interval of more than 10 years (3, 4).  
In contrast, second primary cancers which have developed as 
a result of smoking tobacco develop earlier after exposure. 
Because of this temporal relationship it is possible to link the 
respective risk factor – smoking and alcohol or radiation – to 
the tumor and estimate which one of the two risk factors might 
have caused the SPT. 
Knowledge about PEC associated tumors, who could 
probably be caused by the previous mentioned risk factors 
could be used to prevent the development of PEC by 
avoidance of the known risk factors in the first place and 
screening of the (upper) esophageal tract in the second place. 
In order to ultimately increase survival of patients with PEC, 
it is required not only to focus on the main malignancy, but 
also explore the associated other previous tumors a patient 
with PEC might suffer from. The aim of this research is to 
explore patients which present with PEC and a previous other 
tumor by analyzing data of patients with cancer of the 
proximal esophagus diagnosed between 1989 and 2014 by the 
Netherlands Comprehensive Cancer Organization (IKNL).  
The present research will investigate on PEC, including 
tumors of the cervical esophagus (classified as location 
C15.0) and the upper third of the esophagus, extending from 
the thoracic inlet to the level of the tracheal bifurcation, 
approximately 24 cm from the upper incisor teeth (classified 
as location C15.3). With this retrospective study, we will 
investigate on the prevalence of previous tumors in patients 
with PEC and the influence of those associated tumors on the 
survival as a primary outcome. The hypothesis is that patients 
with PEC will have a high prevalence of tumors of the 
aerodigestive tract, meaning H&N, ESCC and lung cancers 
and that these occur only a short time interval before the 
diagnosis of PEC, suggesting a more prominent role of risk 
factors in the evolution of a second tumor, and a limited role 
for treatment-induced influence on the development of the 
PEC. In addition, we hypothesize that the survival of patients 
with PEC is lower in patients who have already suffered from 
another primary tumor, due to morbidity after the previous 
treatments, and possible constraints in treatment options for 
PEC, e.g. after extended radiotherapy for a previous H&N 
cancer. 
 
METHODS 
Data gathering and database 
Data were obtained from the Netherlands Cancer Registry 
(NCR). Our study retrospectively reviewed patients with 
cancer in the upper third of the esophagus, 18-24 cm from the 
incisor teeth (C15.3) and the cervical esophagus (C15.0, 
CEC), which is up to 18 cm distant from the incisor teeth were 
included, diagnosed in the period 1989-2014. Patients with 
metastatic disease at primary diagnosis were excluded, since 
they have a lower Overall Survival (OS) and would therefore 
bias the results. The cohort consisted of 2184 patients, of 
which 202 were lost to follow-up, meaning they were alive at 
the end of the study, and 1992 reached the endpoint, namely 
death. Follow-up was complete until February 1st 2016 as this 
was the last moment of registration. 
The first steps of the database were to set up some new 
variables, which were not given in the original database For 
example, the treatment variables which were each a 
dichotomous variable had to be put into one 
categorical/nominal variable. Treatment given within a 
period of 9 month after diagnosis was included in the 
registry. As the TNM staging has changed esophageal in 
2010 in a quiet extensive way, the TNM stages of the 
patients were recoded to the TNM6 classification by an 
experienced clinical statistician into a comparable stage 
(27). 
Statistical analyses  
Type of previous tumor was analyzed for the whole 
population using the restructured database. Differences 
between expected and observed frequencies of previous 
tumors types between men and women and between AC and 
SCC were determined by a chi-square test, a z-test with 
Bonferroni correction was done for comparison of the 
properties. Time between diagnosis of previous tumor and 
diagnosis of PEC was compared between gender. Similarly, 
location of PEC (C15.0 or C15.3) was analyzed for 
association with previous tumor site.  
Five-year OS was computed using Kaplan-Meier survival 
curves and comparison between groups was executed with 
the log-rank test. Death was the event of failure and the 
endpoint of the study if patients were not lost to follow-up. 
The follow-up time was defined as the time between the 
diagnosis of PEC and the censoring date, which is death or 
the last moment of follow-up. OS was univariately 
compared between patients with and those without previous 
tumors, between the amount of previous tumors, between 
the type of most recent previous tumor and between groups 
of time interval between PEC diagnosis and previous tumor.  
Multivariate analysis was executed using Cox proportional 
hazard model. Confounder variables were determined by 
comparing 5-year OS of the general population and 
evaluating unequal distribution of properties among patients 
with and without previous tumors. Covariates which were 
taken into the Cox proportional hazard model and their 
corresponding categories were morphology, clinical T stage 
and incidence year. Effect modification of gender and 
morphology was analyzed by stratifying the regression 
analysis by the latter variables. The obtained p-values were 
two-sided and a p-value below 0.05 was taken as significant. 
 
RESULTS 
General descriptive statistics of the study population and 
classification by previous tumor presence 
In the used dataset, there were 2194 patients with PEC, of 
which 522 patients had cancer in the cervical region and 
1672 patients had cancer in the upper third of the esophagus. 
The majority was male (56%) and the median age of total 
population was 68 years. All in all, there were 400 (18%) 
patients who had any previous tumor. Of these, 329 (82% of 
previous tumor group) patients had one previous tumor, 52 
(15%) had two previous tumors, 20 had three previous 
tumors (5%) and three had four previous tumors (0.75%).  
When comparing characteristics of patient with and without 
a previous tumor, there was no difference between those two 
groups regarding the mean of age or the distribution within 
age groups. There was a significant difference in groups 
regarding diagnosis year, as in the first two time intervals 
less previous tumors were diagnosed and the mean follow-
up. The follow-up time was significantly lower in the 
previous malignancy group (1.2 years vs. 1.6 years; p<0.05).  
Patients with previous malignancies have a higher 
proportion of SCC in comparison to patients without a 
previous malignancy. Regarding TNM tumor status, there 
was no association observed in N and M classification, 
although T classification shows a significant association, 
which expresses in a trend towards a higher percentage of  T4 
status in patients without previous tumors.  
There were 493 previous tumors observed in 400 patients, 280 
tumors in 228 men and 213 tumors in 172 women. 58% of the 
tumors presented in men and 42% of tumors presented in 
women.  
More than half of the tumors in men were H&N tumors, 
followed by urogenital tumors with 16% and lung cancers 
with 10%. GI tumors and tumors of the skin represented 8% 
of previous tumors, while tumors of the lymphatic system and 
other tumors only had a marginal proportion (2% respectively 
1%). In women, H&N cancer had a lower proportion in 
comparison to men with 37% (p<0.001). Breast cancer made 
up exactly one quarter of previous tumors in women, while 
lung cancer was only present in 5% of patients, which was a 
significant lower portion than in men (p=0.039). Urogenital 
cancer was half as prevalent in women than in men, while a 
prevalence of 6% of cancers of the lymphatic system was 
signifianctly higher than in men (p=0.041). 
Interval between previous tumor and the occurence of PEC 
Another parameter analyzed was the time between the 
diagnosis of the previous tumor and the diagnosis of PEC in 
order to gain information about possible underlying risk 
factors. In men, H&N and GI cancers had the highest 
percentage of synchronous tumors. Skin, urogenital and 
lymphatic system cancers had the highest proportion of 
tumors being diagnosed in the interval “1 to 5 years” prior to 
PEC occurrence. In women, the cancer types with the highest 
synchronous occurrence were H&N, GI and lymphatic system 
cancers. Lung, H&N, skin and urogenital cancers had a 
comparable number of tumors within 1 to 5 years before PEC. 
The highest proportion of malignancies in the “6 to 10 years” 
interval was those of the lymphatic system and the lowest one 
was in the urogenital system. 
Previous tumors stratified by primary tumor location 
In order to investigate on possible association between the 
tumor location of PEC, prevalence data on previous tumors 
were compared between C15.0 location and C15.3 location. 
CEC had a significantly higher percentage of H&N cancer in 
comparison to tumors located in the upper thoracic esophagus 
(p<0.05). Tumors in the latter position had a slight trend of 
increased prevalence of GI, lung, skin, breast and urogenital 
cancer, but this was not significant. 
Survival Analysis with Kaplan-Meier and Cox regression 
The survival was lower in patients with a previous 
malignancy, although this was not significant (p=0.07) with a 
1-year survival of 38% in patients with a previous tumor and 
42% in patients without 
a previous tumor (see 
Figure 1). 
 Five-year survival was 
9% and 12% (p=0.069). 
There is a significant 
difference between 
synchronous previous 
tumors and tumors 
which are diagnosed 
more than 10 years 
before PEC (p=0.02), 
with 1-year survival 
rates of 30% vs. 43% 
and  5-year survival 
rates of 2% vs. 14%. Addtionally, there was a decreased 
survival when comparing patients without a previous tumor 
Figure 1.  Survival of patients with 
previous tumor vs. patients without 
previous tumor 
Follow-up [in years] 
Existing previous tumor 
No previous tumor 
and patients with a synchronous second primary cancer   
(p=0.031). 
As the former patient group has a 1-year survival rate of 
30% and the latter group a 1 year survival rate of 43% in 
accordance with the population without a previous tumor. 
Compared with patients without a previous malignancy, 
survival in patients with synchronous tumor was also 
decreased. A trend could be seen in the survival of patients 
depending on the amount of previous tumors, but this did 
not reach significant level). Only borderline significance 
was observated in the 5-year survival rate of patients with 
no previous tumor and two previous tumors (8% vs. 0%, 
p=0.037).Patients with more previous tumors had a lower 
OS  than those who had less or no previous tumor.Survival 
was highest for patients who had previous tumor of the skin 
with 5-year survival rates of 20% and a median survival of 
38 months. This reached significant level when compared to 
H&N cancer (p=0.035), GI cancer (p=0.03), lung cancer 
(p=0.004) and urogenital cancer (p=0.036). The lowest 
median survival was observed in cancers of the lymphatic 
system (16 month) lung (16.5 months) and GI cancer (17.8 
month).  
Multivariate analysis using Cox proportional hazard model 
In univariate analysis, there was no significant influence of 
previous tumors on survival observed. Nevertheless, in 
multivariate analysis, there was a significant difference in 
the hazard ratios (HR: 1.237, CI: 1.101-1.390). When Cox 
regression was stratified by gender, previous tumors had an 
influence in survival in men and women, while this effect 
was stronger in women, which makes female gender an 
effect modificator for the effect previous tumors have on 
survival in patients with PEC. Cox regression was also 
stratified by morphology, which showed that previous 
tumors only had an influence on survival in patients with 
SCC. This could be seen in the univariate analysis, and with 
a higher significance in the multivariate analysis.  
 
DISCUSSION 
This research includes the largest retrospectively cohort of 
patients with PEC, with extensive information on previous 
tumors. We confirm the high prevalence of  H&N cancers in 
the PEC population, which constitutes half of previous 
tumors. Men have a higher percentage of H&N cancers and 
lung cancer compared to women. This might be caused by a 
higher percentage of alcohol and tobacco use in the male 
population (5). In both male and female, T stage of PEC was 
lower in patients who had previous tumors, implicating a 
diagnosis due to screening or a faster intervention in case of 
complaints. This was in concordance with a study by 
Natsugoe et al.  who found an earlier T stage in patients with 
a previous tumor (6). 
Kaplan-Meier-Curves did show that there is a trend towards 
decreased survival in patients with previous tumors, 
although this was not statistically significant. Additional 
multivariate analysis by means of a Cox proportional hazard 
regression showed that survival was statistically significant 
decreased in both men and women with previous tumors, 
with a stronger effect in women. This could be due to the 
fact that men had a worse basic survival in comparison to 
women and than the effect of a previous tumor does not 
score as high as in women.  
Léon et al. found that the survival of patients with H&N 
cancer decreases with number of subsequent tumors (7).  
Although in our dataset we looked retrospectively on 
previous tumors, while this study investigated on 
development of subsequent cancers, the consensus is 
comparable and the existence of multiple primary cancers 
decreases OS tremendously. In our analysis there also was a 
trend towards a proportional decrease of survival depending 
on the amount of previous tumors. A study on previous 
tumors in esophageal cancer done by Lo et al. has shown that 
H&N cancers appear in 7 % of ESCC and more often in men 
and the most prevalent tumor within the H&N cancer group 
was hypopharyngeal cancer (8). In our study, 8% of the total 
population of PEC did have a second primary H&N cancer. 
We also showed that patients with CEC did have a more 
pronounced prevalence of H&N cancer, which supports the 
theory of field cancerization as the cervical esophagus is 
closer to the H&N area. Also in line with our study was a 
significantly lower OS in patients with previous H&N cancer 
than in patients without a previous cancer. It is important to 
note that the high prevalence of some tumors might not be 
caused mainly due to the risk factors, but because an inherent 
increased lifetime risk of some tumors. This especially holds 
true for prostate cancer and breast cancer, which have one of 
the highest prevalences amongst cancers in the general 
population for men and women respectively (9). It is crucial 
to be aware of this fact in order to avoid over-interpretation of 
our data. Within our study we intended to compare our 
prevalences of the different tumors with data of the general 
healthy Dutch population, but this turned out to be more 
complicated than previously expected and was therefore kept 
for future studies.  
A strength of the present study is that is has extensive data on 
a specific and rare type of esophageal cancer with 
comprehensive information of the associated previous tumors 
during a more than 20-year lasting follow-up period. These 
previous tumors might have comparable risk factors as those 
of PEC and can therefore give insights into the concept of 
field cancerization in PEC and H&N cancer. The research 
strategy is unique within the field of PEC as to our knowledge 
no study exists which considers patients’ past tumor history. 
Associated with this, we acknowledge an important limitation 
in the retrospective nature of our study, considering we can 
not provide an overview of the subsequent tumors associated 
with PEC. It might be of interest to know more about other 
tumors patterns after the diagnosis of PEC. Literature shows 
that patients with a tumor in the aerodigestive tract have a 
high risk of other primary tumors in that area, especially when 
exposure to risk factors continues after diagnosis of the index 
tumor  (10, 11). 
Our study has shown that especially previous H&N tumors 
can have a large impact in cancers of the proximal esophagus 
as they decrease survival in both men and women and 
therefore worsen clinical outcome in patients diagnosed 
within the curative setting, i.e. non-metastasized disease. 
These results can affect clinicians to take patients’ previous 
tumor history into account during treatment decision-making. 
This especially holds true for tumors which occurred within 
the 5-year interval of the diagnosis of PEC. In order to be able 
to distinguish second primary tumor from metastasis or 
recurrent there needs to be consensus on the used definitions. 
In our study, tumors were classified as being synchronous 
when they were in the same calendrary year. Of course this 
gives the possibility of a tumors being nearly two years apart 
and still classified as a synchronous tumor and on the other 
hand, tumors which occurred in the end and in the beginning 
of the subsequent year, are also misclassified as they are only 
seperated by a few month.  
Further studies are needed to investigate further on the pattern 
of occurrence of previous tumors and together with data of the 
histopathology of the previous tumor and exposed risk 
factors, prediction (models) of PEC should be set up. The 
comparative study by de Vos-Geelen et al. about different 
regimes of definitive chemoradiation is ongoing, but study 
results were not sufficiently available until the end of this 
research period. This study includes parameters like 
comorbidities, smoking and alcohol consumption, previous 
and subsequent malignancies and therefore could serve to 
gain further knowledge of the association between the 
previous mentioned factors and associated tumors of PEC 
which could then be used to improve prevention of PEC. 
Likewise, some other studies come to the conclusion that 
stringent surveillance for malignancies is important in 
patients with H&N cancer, particularly in those with 
hypopharyngeal cancer, as patients with this type of cancer 
are most likely to develop ESCC (12). For successful 
implication into the clinic it is of utmost importance that all 
diagnostic modalities are used for tumor staging and that an 
appropriate (molecular) distinction is being made between a 
previous primary tumor in order to treat  the patient 
according to the correct setting (13). A smooth cooperation 
between the general physician and the different specialists 
in the clinic is crucial for appropriate patient information 
transfer and ro avoid information gaps regarding previous 
tumor history. This would be an important step towards the 
prevention of PEC and improvement of survival and quality 
of life in cancer patients.  
 
CONCLUSION 
In this study we showed that patients with PEC have a high 
prevalence of previous tumors with an influence on  OS. In 
addition to continued exposure to similar risk factors, the 
term field cancerization is a possible explanation for the 
high prevalence of second tumors in this population. More 
research is needed to explore the effectiveness of strict 
prevention and surveillance programs, which could 
contribute to a decreased rate of PEC and detect this cancer 
in an earlier stage. 
 
ROLE OF THE STUDENT (MANDATORY) 
My role in this project was to analyze data of the IKNL 
database, which means that I first recoded certain variables, 
grouped values and executed frequency analysis, Kaplan 
Meier Survival Curves and Cox regression.  
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